Inui, Naoki http://orcid.org/0000-0002-4624-7119
Toi, Yukihiro
Yoneshima, Yasuto
Morise, Masahiro
Hata, Akito
Kubota, Kaoru http://orcid.org/0000-0003-0367-2606
Saeki, Toshiaki
Tamura, Tomohide
Funding for this research was provided by:
Taiho Pharmaceutical Co., Ltd.
Article History
Received: 4 June 2023
Accepted: 15 August 2023
First Online: 16 September 2023
Declarations
:
: Naoki Inui received honoraria and grants from Taiho Pharmaceutical. Yukihiro Toi received honoraria from Taiho Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, MSD, AstraZeneca, Chugai Pharmaceutical, Pfizer, and Kyowa Kirin. Yasuto Yoneshima received honoraria from Taiho Pharmaceutical and Takeda Pharmaceutical. Masahiro Morise received funding from the speakers’ bureau of Chugai Pharmaceutical, AstraZeneca, Ono Pharmaceutical, and Eli Lilly; research funding from Boehringer Ingelheim (Inst), Novartis (Inst), AstraZeneca, (Inst), Eli Lilly (Inst), Taiho Pharmaceutical (Inst), Chugai Pharmaceutical (Inst), Ono Pharmaceutical (Inst), Pfizer (Inst), Merck Serono (Inst), and Kissei Pharmaceutical (Inst). Akito Hata provided a consulting or advisory role to Boehringer Ingelheim, Eli Lilly, Chugai Pharmaceutical, AstraZeneca, and MSD; received funding from the speakers’ bureaus of Boehringer Ingelheim, Eli Lilly, Chugai Pharmaceutical, AstraZeneca, and Taiho Pharmaceutical; received research funding from Boehringer Ingelheim (Inst), MSD (Inst), Eli Lilly (Inst), and AstraZeneca (Inst). Kaoru Kubota received honoraria from Bristol-Myers Squibb Japan, Daiichi Sankyo, Boehringer Ingelheim, Taiho Pharmaceutical, Eli Lilly Japan, MSD, Chugai Pharmaceutical, AstraZeneca, Nippon Kayaku, Takeda Pharmaceutical, and Pfizer; and served on the advisory board for Taiho Pharmaceutical. Toshiaki Saeki received grants from AstraZeneca (Inst), Eisai (Inst), Kyowa Kirin (Inst), Daiichi Sankyo (Inst), Taiho Pharmaceutical (Inst), WJOG (Inst), Chugai Pharmaceutical (Inst), Nippon Kayaku (Inst), Novartis (Inst), MSD (Inst), Sawai Pharmaceutical (Inst), Covance Japan (Inst), Maruho (Inst), LabCorp Japan (Inst), Sanofi (Inst), Takeda Pharmaceutical (Inst), and Eli Lilly Japan (Inst); honoraria from Ono Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, ASKA Pharmaceutical, Novartis, AstraZeneca, Eisai, Taiho Pharmaceutical, Takeda Pharmaceutical, Eli Lilly Japan, Pfizer Japan, MiRTeL, and Meiji Seika Pharma. Tomohide Tamura received honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, MSD, Ono Pharmaceutical, Eli Lilly, and Nippon Kayaku.
: This research was a pooled analysis of data obtained from two previous studies. Both previous studies were performed in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and the protocols were approved by the institutional review board of each participating institution. Informed consent was obtained from all individual participants included in the two previous studies from which data were pooled and analyzed in the present study. Consent for publication was not applicable, in our study.